α-Tocopheryl phosphate (TP) is a naturally occurring form of vitamin E found in the body. In the present study we compared the ability of an α-TP mixture (TPM) against a standard vitamin E supplement, α-tocopherol acetate (TA) on the development of atherosclerotic lesions in ApoE-deficient mice. Mice were maintained on either a normal chow diet for 24 weeks (Normal Diet), vs a group in which the final 8 weeks of the 24-week period mice were placed on a high fat (21%), high cholesterol (0.15%) challenge diet (HFHC), to exacerbate atherosclerotic lesion development.. The difference in these two control groups established the extent of the diet-induced atherosclerotic lesion development. Mice in the various treatment groups received either TA (300 mg/ kg chow) or TPM (6.7-200 mg/kg chow) for 24 weeks, with TPM treatment resulting in dose-dependent significant reductions in atherosclerotic lesion formation and plasma levels of pro-inflammatory cytokines. TA-treated mice, with the tocopherol equivalent TPM dose (200 mg/kg chow), showed no significant reduction in plasma lipid levels or evidence for aortic lesion regression. At this TPM equivalent TA dose, a 44% reduction in aortic lesion formation was observed. In addition, these TPM treated mice, also showed a marked reduction in aortic superoxide formation and decreased circulating plasma levels of known pro-inflammatory markers IL-6, MCP-1, IL-1β, IFN-γ and TNF-α. These findings indicate that TPM treatment slows progression of atherosclerotic lesions in ApoE-deficient mice with this effect potentially involving reduced oxidative stress and decreased inflammation.
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| INTRODUCTION
Vitamin E or tocopherol as a cardio-protective agent has been examined in a variety of studies in animals and humans. Elevated oxidative stress, lipids, inflammation and endothelial dysfunction are believed to contribute to the development of cardiovascular disease. [1] [2] [3] [4] Strategies targeting the reduction of these via antioxidant supplementation have been extensively studied in human and animal models. [5] [6] [7] [8] [9] Increased intake of α-tocopherol (vitamin E supplementation), has been shown to have protective effects against heart disease, while low levels of α-tocopherol (vitamin E) has long been associated with increased incidence of coronary heart disease. 6, 7 Vitamin E supplementation in ApoE-deficient mice has previously been shown to supress isoprostane generation and atherosclerosis. 9 Inhibition of smooth muscle cell proliferation, preservation of endothelial function, inhibition of monocyte-endothelial adhesion, inhibition of monocyte reactive oxygen species and cytokine release, and inhibition of platelet adhesion and aggregation are all factors that have been demonstrated in vitro by the use of vitamin E and contribute to its potential anti-atherosclerotic properties.
10-13
However, human clinical trials using vitamin E to examine potential anti-atherosclerotic properties in vivo have been equivocal and in most cases show no effect. [14] [15] [16] [17] Current vitamin E supplements alone are therefore not a useful clinical option to combat atherosclerosis and inflammation.
Novel tocopherol derivatives have been previously described by our laboratory and collaborators including the α-tocopheryl phosphate ester (TP) and the di-α-tocopheryl phosphate ester (T 2 P). TP is the ester derivative of phosphate with the hydroxyl group of tocopherol, while T 2 P is obtained by esterification of two tocopherol moieties with one phosphate molecule. 18 Tocopheryl phosphate mixture (TPM), also referred to in the literature as mixed tocopheryl phosphates (MTP), is made up of a mixture of these two phosphorylated forms of α-tocopherol, (ie contains α-tocopheryl phosphate (TP) and α-ditocopheryl phosphate T 2 P in a 2:1 ratio by weight).
In this context, we have shown that TP, like α-tocopherol, is a naturally occurring compound. Many in vitro and in vivo effects of TP have been described, including its ability to inhibit the proliferation of a number of cell types including aortic smooth muscle cells and monocytes, apoptosis, signal transduction and gene expression, all of which are key players in the formation of atherosclerotic lesions. 18, 19 This activity appears to be more potent than that of its unphosphorylated counterpart, and provides a possible avenue for potential benefits for cardiovascular disease (CVD) intervention. Indeed, animal studies using TPM supplementation, but not α-tocopheryl acetate (TA), have been shown to prevent the progression of atherosclerosis and ischaemia/reperfusion injury. 20, 21 Therefore, the aim of the present study was to assess the effects of TPM and TA (at an equivalent upper TPM dose) in a commonlyused murine model of atherosclerosis, the apolipoprotein E-deficient (ApoE −/− ) mouse, treated for a total of 24 weeks, with mice placed on a high fat (21%), high cholesterol (0.15%) challenge (HFHC) diet in the final 8 weeks to exacerbate the atherosclerotic lesion development. In particular, we have examined the effects of the tocopherols on plasma lipid profiles and the progression of aortic lesions in ApoE −/− mice.
| RESULTS

| Analysis of food consumption and dosing with the tocopherol compounds
Animals gained weight throughout the experimental period at a similar rate (Table 1) , and food (Table 1 ) and water (data not shown) consumption were also similar and did not differ between treatments. As described earlier, the tocopherol equivalent dose delivered to each of the TA and TPM treatment groups were not considered significantly different ( Table 1 ).
The average daily doses of the various tocopherol compounds were calculated for each of the five doses in terms of tocopherol equivalent (TE) doses based on molecular weight comparisons with α-tocopherol. 
| Plasma lipid concentrations
Following the 16 weeks of treatment (induction phase), TA had no effect on plasma lipid levels compared to control HFHC mice. In contrast, there appeared to be a dose dependent reduction in TC, TG and LDL-C levels in TPM treated mice, however, only the higher doses (Table 2 ). Plasma TC, TG, LDL-C and HDL-C all increased at the end of the challenge period in all HFHC fed mice and TPM treatment at all doses had no long-lasting effects on final lipid profile of the mice (Table 2 ). 
| Atherosclerotic lesion development
| Superoxide expression
Dihydroethidium staining was used to localise superoxide levels within aortic sections taken from control ND and control HFHC fed mice, and also mice fed a HFHC diet that were treated with tocoph- 
| Plasma biomarker measurements
Measurements of plasma biomarkers were conducted in plasma samples from control ND and control HFHC fed mice, and also mice fed a HFHC diet that were treated with TA (at 300 mg/kg chow) and TPM 
| DISCUSSION
Commercially, vitamin E is available in different forms, but commonly the vitamin E acetate or α-tocopherol acetate (TA; in either natural
, is the analogue most often used in food supplements and in cosmetics as it is considered more stable due to its esterification and therefore protection from oxidation. However the cellular effects of the TA form of vitamin E have lower biological activity than the non-esterified vitamin E, α-tocopherol. with α-tocopherol present in both phosphorylated (TP) and dephosphorylated forms, suggesting that its interconversion in the body may be important for its absorption and cellular functions. 27, 28 We have previously demonstrated potential anti-atherogenic, effects of TPM, with significant inhibition of cell proliferation and gene expression in vitro, and reduction in lesion development in a hypercholesterolemic rabbit model of atherosclerosis, compared to α-tocopherol or the acetate form (TA). [18] [19] [20] The results of the current study in the commonly used ApoE −/− mouse model of atherosclerosis are consistent with our previously reported atheroprotective effects of TPM in the rabbit, and also demonstrate mechanistic effects of TPM involving reductions in plasma lipids, oxidative stress and proinflammatory cytokines/chemokines.
Decreased circulating cholesterol levels, particularly LDL-C, are well known to reduce atherosclerosis in animal models. 29 Following TPM treatment, TC and LDL-C were significantly reduced after the induction phase, however this effect was not maintained through the challenge phase. Although plasma cholesterol levels were equivalent following challenge with the HFHC diet, we still observed a significant 44% reduction in lesion development at the highest TPM dose.
Thus the final lesion content at the end of treatment was subsequently reduced in mice treated with TPM. In light of the fact that the TA equivalent TPM dose (ie 200 mg/kg chow) caused striking reductions in oxidative stress and in known pro-inflammatory biomarkers in plasma, changes beyond the lipid lowering effect of TPM cannot be underestimated.
The superoxide anion is well recognized as a major mediator of oxidative stress and subsequent pro-atherogenic effects such as LDL oxidation, regulation of adhesion molecules and cellular proliferation and inflammation. [30] [31] [32] [33] In addition to the known antioxidant effects of α-tocopherol, 34 the beneficial effects of TPM observed in the current study may reflect TP-mediated inhibition of the production of superoxide by predominant sources such as NADPH oxidase. 35 This is well supported as α-tocopherol has previously been shown to inhibit the assembly of NADPH oxidase subunits and subsequently superoxide production. 36 Interestingly, beneficial effects of vitamin E have been reported in LDL receptor-deficient mice independent of a reduction in cholesterol levels, but was associated with significant suppression of oxidative and inflammatory reactions following vitamin E supplementation. 5 Therefore, although lipids were not reduced following the challenge phase, reductions in superoxide following TPM treatment may account for the decreased lipid deposition as well as subsequent reductions in circulating plasma biomarker levels.
Our findings are consistent with a previous study in which a 2% cholesterol diet was fed to New Zealand albino rabbits for 4 weeks in the absence or presence of TPM or TA. 20 TPM-treated rabbits showed no significant change in the plasma lipid levels but exhibited a reduction in plaque formation compared to controls. Thus, in both studies
, in the face of deliberately-elevated plasma lipids, the same dose of TPM in the 2 animal models exerted similar macroscopic protection against plaque formation in the aortae of these animals.
However, the current study also identified changes in oxidative stress which may account for reductions in inflammation, as a possible mechanism in TP mediated atheroprotection.
Although oxidative stress has been linked with a pro-inflammatory response, non-antioxidant mediated effects of TP, including antiinflammatory properties independent of reductions in superoxide cannot be excluded. In rabbits, TP caused a reduction in CD36 scavenger receptor expression. 20 The CD36 scavenger receptor has a pivotal role in the uptake of oxidized LDLs (oxLDLs) from the bloodstream.
T A B L E 1 Body weight and food consumption (g; mean ± SEM) during the 'normal diet' and high fat, high cholesterol challenge phases of the study Where appropriate, data are given as the mean ± SEM; N/A, not applicable; TA, tocopheryl acetate; TPM, tocopheryl phosphate mixture; TE, tocopherol equivalent, calculated based on molecular weight comparisons with α-tocopherol.
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The TE equivalent TA and TPM doses, which are used in subsequent analysis (ie the TA 300 mg/kg chow dose and TPM 200 mg/kg chow dose). α-Tocopherol has the ability to act as an antioxidant or free radical scavenger, while at the same time may also be a potential source of free radicals. 38 Interestingly at a cellular level α-tocopherol also has other functions not related to its redox chemistry which are commonly referred to as the non-antioxidant roles of vitamin E, however the exact molecular mechanism of α-tocopherol or vitamin E is still not completely understood. 11, 22, 39 The discovery that TP is another natural form of vitamin E, and can be synthesized by human coronary artery cells and mast cells, along with increased levels of α-tocopherol in cells indicates that endogenously cells may convert α-tocopherol to TP (ie α-tocopherol can be phosphorylated to TP, and/or TP can be de-phosphyorylated). 27 TP's potent non-antioxidant effects, and the ability for it to interconvert to α-tocopherol and vice versa in the body, has offered a potential hypothesis to explain the observed non-antioxidant roles of vitamin E. 22 For example, in cultured human aortic smooth muscle cells (HASMC), TP but not α-tocopherol, inhibited CD36 mRNA expression, indicating possible disparate roles for the two compounds.
T A B L E 2 Mouse plasma lipid level comparisons (mmol L
−
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This is in line with the fact that in the current study, TP was more effective than TA in reducing oxidative stress and levels of inflammatory markers (Figure 4) .
Interestingly, an important observation from the current study was that TPM, but not TA at equivalent tocopherol doses, caused a marked 40 We have demonstrated an atheroprotective effect and future studies will be targeting the lesion complexity following TPM treatment. Doses of TA and TPM were monitored and adjusted to approximate equivalent tocopherol levels (at the highest TPM dose; 200 mg/kg chow), and particular care was taken to provide a modified diet that was low in vitamin E in order to avoid confounding effects on treatments. However, in contrast to previous reports by Pratico et al. 8 and Cyrus et al., 5 we did not observe protective effects of vitamin E (TA) in our model of atherosclerosis. An important distinction between our study and those previously documented, is that our dose of TA was substantially lower (5-10 fold) with mice receiving 200 mg/kg chow compared to 1000-2000 mg/kg chow. 41 The dose of TA was chosen to approximate an equivalent tocopherol load as that of TPM. Since our previous reports have documented that TP at 200 mg/kg chow was protective in hypercholesterolemic rabbits, we used the same dose and thus our TA dose was also reduced accordingly. Importantly, we have demonstrated results consistent with previous rabbit studies which further highlights the potency of TP, but also may explain disparate effects of TA in our study compared with previous reports.
In conclusion our results indicate that TPM treatment reduced the development of lesion formation in ApoE-KO mice, and thus may represent a novel treatment strategy in the setting of atherosclerosis.
Mechanistically, the present study also indicated anti-oxidative and/ 
| Blood sampling
After 7 days of adaptation, blood samples were taken from the tail vein to establish the initial baseline plasma lipid parameters. Plasma lipid analyses were also performed at week 16 (the end of the normal diet administration or 'induction phase') and at the end of week 24
(following the 8 weeks on the high fat, high cholesterol challenge diet or 'challenge phase'). At this time, animals were killed by CO 2 asphyxiation and blood was collected from the right ventricle.
| Plasma lipid measurements
For plasma lipid measurements, total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) levels, in 250 μL of plasma was independently analysed (Gribbles Veterinary Pathology, Melbourne, Australia) using enzymatic in vitro tests for direct quantitative determination of lipids in plasma on automated clinical chemistry analysers (Roche/Hitachi 912/917). Plasma lipid levels were measured at baseline, after the induction phase and at the end of the experiment using enzymatic assays.
| Quantification of atherosclerotic plaques
In each group atherosclerotic lesions were measured using en face staining with oil red O in the longitudinally cut aorta as previously described. 40 Imaging was performed using the Moticam-480P Digital Camera and quantitated using the appropriate software (Motic Images Plus 2.0). Lesion area was expressed as a percentage of the total luminal area of the vessel.
| Localization of superoxide by dihydroethidium staining
Superoxide measurements were obtained in a subset of n = 7 mice/group to examine the influence of TA and the approximate tocopherol equivalent (TE) TPM dose (ie 200 mg/kg chow) on oxidative stress. Dihydroethidium (DHE; 2 μmol L −1 ) was used as previously described 40 to detect superoxide in frozen aortic sections 
| Plasma biomarker measurements
Plasma levels for known pro-atherogenic biomarkers including interleukin (IL)-1β, IL-6, monocyte chemoattractant protein-1 (MCP-1), tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), were measured using a Bio-Plex cytokine assay (Mouse cytokine 5-plex panel,
Bio-Rad, Australia). The detection range was 0.5-32 000 pg/mL and assays were performed according to the manufacturer's instructions.
| Statistical analysis
All results are expressed as mean ± SEM. Statistical comparisons were done by one-way analysis of variance (ANOVA) with Bonferroni corrections where appropriate using Graphpad Prism version 5 (Graphpad Software, San Diego CA, USA).
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